[Asia Economy Reporter Hyunseok Yoo] Quantamatrix, a comprehensive microbial diagnostic company, announced on the 15th that its rapid antibiotic susceptibility testing system 'dRAST' has been adopted as a sepsis diagnostic device by Germany's Limbach Group.
The Limbach Group is Germany's largest medical testing institution, formed by merging several independent laboratories. It manages extensive laboratory diagnostics, including 30 clinical laboratories within Germany. To enhance convenience for patients, clinical laboratories, and clinicians, the Limbach Group has officially introduced Quantamatrix's dRAST. The dRAST system is being prioritized for use at the Limbach Group's key laboratory, ‘MVZ Labor Ravensburg’.
Dr. Ulrike Schumacher, Medical Director of the Microbiology Department at MVZ Labor Ravensburg, stated, “dRAST has perfectly established itself in the Limbach Group laboratories, which handle about 1,000 patient blood culture samples daily from approximately 100 hospitals. Since adopting dRAST, we have been able to reduce the waiting time for results by about two days, allowing patients to be quickly diagnosed with the appropriate antibiotics.”
She added, “The biggest advantage of dRAST is its extremely simple usage, enabling antibiotic susceptibility testing to be performed during evenings, holidays, and weekends.”
Seonghoon Kwon, CEO of Quantamatrix, said, “Blood infections caused by bacteria require rapid detection, and without treatment with the correct antibiotics, patients can die. Quantamatrix’s dRAST product rapidly identifies the optimal antibiotic tailored to the patient and ensures optimized treatment methods that reduce toxicity caused by widespread antibiotic misuse, thereby increasing patient survival rates.”
He continued, “The adoption of dRAST by Germany’s Limbach Group signifies that our product can be utilized in automated, large-scale laboratories to provide ultra-rapid sepsis testing services to many hospitals. We expect this to accelerate the adoption of dRAST across Europe in the future.”
Meanwhile, this adoption was concluded through a partnership with ‘Axonlab,’ a leading supplier of in vitro diagnostic solutions, following successful feasibility validation of Quantamatrix’s dRAST platform at Reference Laboratories. Quantamatrix plans to promote dRAST in European countries including Germany, Switzerland, Austria, and the Benelux region through collaboration with Axonlab.
Quantamatrix specializes in in vitro diagnostics using microbial diagnostic technology and provides integrated solutions within the sepsis value chain. The company is currently establishing a distribution network across Europe and actively targeting global markets, including entry into the Middle East and Africa.
The flagship product, dRAST, is a rapid antibiotic susceptibility testing system that prescribes the optimal antibiotic within 4 to 6 hours after a positive blood culture. Utilizing patented microfluidics and artificial intelligence technology, it delivers optimal antibiotic prescription results two days faster than conventional tests. dRAST has obtained new medical technology certification, has been covered by national health insurance in Korea since last November, and has completed its EMEA (Europe, the Middle East, and Africa) distribution network to conduct aggressive marketing.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
